A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with Alzheimer's Disease
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Edonerpic (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Toyama Chemical
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 04 Jun 2016 New trial record